- Pressemitteilung BoxID 136602
4SC AG Receives Research Grant from the Bavarian Research Foundation
The consortium composed of 4SC, Kinaxo Biotechnologies AG, Martinsried, Germany, and the Virological Institute of the Erlangen University Hospital, Germany, will receive EUR 700,000 for this three year project. The research project will focus on the discovery of small-molecule kinase inhibitors with a dual-mode of action that can selectively inhibit viral and cellular protein kinases. Kinase inhibitors are a commonly used drug class in cancer and inflammation as they can modulate signalling pathways in cells which can lead to various disease states. In viral diseases, current molecular treatments inhibit either a viral target or a target in the infected host cell. However, this approach allows viruses to build resistance quickly, as they are able to mutate and continue to replicate in host cells. By investigating protein kinase inhibitors in viral diseases, it is hoped that a dual-mode of action could target the virus and host cells concurrently, thereby potentially delaying a resistance to treatments for longer.
Dr Daniel Vitt, Chief Scientific Officer at 4SC AG, commented, 'We are pleased to have received this research grant in order to support our drug discovery. At 4SC, research is an integral part of our business strategy as it ensures the future generation of clinical drug candidates for our pipeline. Working closely with research institutions and companies is an important part of this process as it helps us to remain at the forefront of new research and drive the innovation required to develop more effective medicines for patients in the future.'
This document may contain projections or estimates relating to plans and objectives relating to our future operations, products, or services; future financial results; or assumptions underlying or relating to any such statements; each of which constitutes a forward-looking statement subject to risks and uncertainties, many of which are beyond our control. Actual results could differ materially, depending on a number of factors.
4SC AG (ISIN DE0005753818) is a drug discovery and development company focused on autoimmune and cancer indications. The company currently has three clinical programs, with three further clinical trials planned to commence in 2009. 4SC-101, a small molecule, is in a Phase IIb study in rheumatoid arthritis as well as in a Phase IIa exploratory study in inflammatory bowel disease. The company's lead oncology compound, 4SC-201, a histone deacetylase (HDAC) inhibitor, is in a Phase II trial in hepatocellular carcinoma and is due to commence a further Phase II trial in Hodgkin's lymphoma in 2009. Drug candidates are developed until proof-of-concept in order to generate value creating partnerships with the pharmaceutical industry in return for advance and milestone payments as well as royalties.
4SC was founded in 1997, has 93 employees, and is listed on the Prime Standard of the Frankfurt Stock Exchange since December 2005. For further information please visit www.4sc.com.
Diese Pressemitteilungen könnten Sie auch interessieren
Seit 2016 läuft das Projekt zum Aufbau eines ambulanten Hospizdienstes für Gehörlose in Bayern. Hier werden Gehörlose zu Hospizbegleitern in...
Was ändert sich in Familien, wenn ein Familienmitglied Diabetes bekommt? Wie beeinflusst der Diabetes auch den Partner/die Partnerin? Autorin...